back to Directory

Anima Biotech

Anima Biotech logo

Website
https://www.animabiotech.com/
Founded
2014
Patents
8
Publications
5

Technologies

AI Companies (Drug Discovery) RNA-focused Startups

Anima Biotech is advancing mRNA Lightning, a novel platform for the discovery of selective small molecule mRNA drugs and their mechanisms of action. Our differentiated approach combines high-scale phenotypic screening that automates millions of experiments in live mRNA biology with MOAi technology using AI to elucidate the mechanism of action of active molecules.

This unparalleled level of automation of phenotypic screening of mRNA modulators together with our AI-driven MOA elucidation enabled us to develop a broad pipeline across 18 different discovery programs in various therapeutic areas. With our deep expertise in mRNA biology, we were able to advance them at unprecedented speed and success rate.

Anima wholly-owned pipeline programs are in Fibrosis (Collagen I mRNA biology modulators, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), Oncology (c-Myc mRNA biology modulators and mutation agnostic mKras mRNA biology modulators), and Neuroscience (Tau - Alzheimer's disease and Pain - Nav1.7 mRNA biology modulators).

In addition to our own pipeline, we established strategic collaborations with Pharma in partnered programs including our collaborations with Lilly and Takeda Pharmaceuticals.

Interviews

Posts Mentioning This Company

14 Cutting-Edge Startups Focusing On RNA Research

  
For many years, the focus of therapeutic developments and scientific research was directed at the genome and proteins. Yet, there is a completely different level of cell regulation: the transcriptome level, presented by ribonucleic acids (RNAs).

What Makes Israel's Life Sciences Ecosystem Successful?

  
Israel's biotech sector has been considered secondary to its thriving Medtech field for decades. Still, the turn of millennia brought a significant shift to the biotech landscape in the country. Part of the growth originates from Israel’s focus on building a solid education with roughly 6% of GDP being spent on …

9 Companies Using Artificial Intelligence to Fight Infectious Diseases

  
Development of a novel drug is a tedious process that requires immense investments of resources and time - on average, it takes at least ten years and $ 2.6 B for a new medicine to complete the journey from initial discovery to the marketplace. And then patents give pharmaceutical companies …